Filtered By:
Source: American Heart Journal
Condition: Bleeding
This page shows you your search results in order of date.
Order by Relevance | Date
Total 167 results found since Jan 2013.
Rivaroxaban Monotherapy versus Combination Therapy According to Patient Risk of Stroke and Bleeding in Atrial Fibrillation and Stable Coronary Disease: AFIRE trial sub-analysis
Publication date: Available online 28 February 2021Source: American Heart JournalAuthor(s): Masaharu Akao, Satoshi Yasuda, Koichi Kaikita, Junya Ako, Tetsuya Matoba, Masato Nakamura, Katsumi Miyauchi, Nobuhisa Hagiwara, Kazuo Kimura, Atsushi Hirayama, Kunihiko Matsui, Hisao Ogawa
Source: American Heart Journal - March 1, 2021 Category: Cardiology Source Type: research
Cost-effectiveness of combined catheter ablation and left atrial appendage closure for symptomatic atrial fibrillation in patients with high stroke and bleeding risk
Publication date: Available online 19 August 2020Source: American Heart JournalAuthor(s): Hiroshi Kawakami, Mark T. Nolan, Karen Phillips, Paul A Scuffham, Thomas H. Marwick
Source: American Heart Journal - August 19, 2020 Category: Cardiology Source Type: research
Impact of creatinine clearance on clinical outcomes in elderly atrial fibrillation patients receiving apixaban: J-ELD AF registry sub-analysis
ConclusionsThe incidence of events in each CCr value group was comparable for stroke or systemic embolism and bleeding requiring hospitalization, and significantly higher for total deaths and cardiovascular deaths only in the CCr 15–29 mL/min group, in Japanese non-valvular AF patients aged ≥75 years.
Source: American Heart Journal - February 9, 2020 Category: Cardiology Source Type: research
Rivaroxaban versus warfarin in patients with non-valvular atrial fibrillation and stage IV-V chronic kidney disease
ConclusionsNo statistically significant difference in the risk of ISSE or major bleeding was found between rivaroxaban- and warfarin-treated patients. While further study is needed, rivaroxaban appears to be a reasonable alternative to warfarin for ISSE prevention in the setting of NVAF and stage IV-V CKD.
Source: American Heart Journal - January 22, 2020 Category: Cardiology Source Type: research
Risk of Major Cardiovascular and Neurologic Events with Obstructive Sleep Apnea among Patients with Atrial Fibrillation
ConclusionAmong patients with AF, OSA is an independent risk factor for MACNE and, more specifically, stroke/SE.Graphical Abstract
Source: American Heart Journal - January 7, 2020 Category: Cardiology Source Type: research
Ticagrelor-based antiplatelet regimens in patients with atherosclerotic artery disease—A meta-analysis of randomized clinical trials
ConclusionsIn patients with atherosclerotic artery disease, the benefit of ticagrelor-based therapies was confined to patients treated for coronary artery disease. The drug significantly reduced the risk for all-cause death and MI without excess risk of bleeding in these patients. In consideration of limitations of subgroup analyses, these results need further validation.
Source: American Heart Journal - November 20, 2019 Category: Cardiology Source Type: research
Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the ARISTOTLE trial
ConclusionsIn patients with AF on oral anticoagulants, prior GIB was associated with an increased risk of subsequent major GIB but not stroke, intracranial bleeding, or all-cause mortality. For the key outcomes of stroke, hemorrhagic stroke, death, and major bleeding, we found no evidence that the treatment effect (apixaban vs. warfarin) was modified by a history of GIB.
Source: American Heart Journal - November 2, 2019 Category: Cardiology Source Type: research
Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease
Publication date: Available online 23 October 2019Source: American Heart JournalAuthor(s): Robert C. Welsh, Eric D. Peterson, Raffaele De Caterina, Christoph Bode, Bernard Gersh, John W. EikelboomAbstractFor four decades, anti-thrombotic therapy with aspirin has been a cornerstone of secondary prevention for patients with chronic atherosclerotic cardiovascular disease (ASCVD). Unfortunately, despite the use of evidence-based therapies, patients with ASCVD continue to have recurrent major adverse cardiovascular (CV) events including death, myocardial infarction and stroke -- at a rate of approximately 2–4% per year. To co...
Source: American Heart Journal - October 24, 2019 Category: Cardiology Source Type: research
Outcome impact of different tranexamic acid regimens in cardiac surgery with cardiopulmonary bypass (OPTIMAL): Rationale, design, and study protocol of a multi-center randomized controlled trial
ConclusionsThe study is designed to identify a TxA dose with maximal efficacy and minimal complications. We hypothesize that the high dose has superior efficacy and non-inferior safety to the low dose.
Source: American Heart Journal - October 22, 2019 Category: Cardiology Source Type: research
Ticagrelor-based antiplatelet regimens in patients with atherosclerotic artery disease - a meta-analysis of randomized clinical trials
ConclusionsIn patients with atherosclerotic artery disease, the benefit of ticagrelor-based therapies was confined to patients treated for CAD. The drug significantly reduced the risk for all-cause death and MI without excess risk of bleeding in these patients. In consideration of limitations of subgroup analyses, these results need further validation.
Source: American Heart Journal - September 2, 2019 Category: Cardiology Source Type: research
Ticagrelor in patients with heart failure after acute coronary syndromes—Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial
ConclusionsIn patients with ACS, ticagrelor is more efficacious in protecting against new ischemic events and mortality than clopidogrel irrespective of the presence of HF. There is no difference between ticagrelor or clopidogrel treatment in new-onset HF post-ACS.
Source: American Heart Journal - May 18, 2019 Category: Cardiology Source Type: research
Ticagrelor in patients with Heart failure after acute coronary syndromes – Insights from the PLATelet inhibition and patient outcomes (PLATO) trial
ConclusionsIn patients with ACS, ticagrelor is more efficacious in protecting against new ischemic events and mortality than clopidogrel, irrespective of the presence of HF. There is no difference between ticagrelor or clopidogrel treatment in new-onset HF post-ACS.
Source: American Heart Journal - April 18, 2019 Category: Cardiology Source Type: research
Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design
ConclusionsThe TICO trial is an ongoing trial evaluating the efficacy and safety of ticagrelor monotherapy following 3-month DAPT exclusively in ACS patients treated with uniform BP-SES. It may provide novel insights regarding the need for adjusted use of DAPT for rebalancing risk–benefit in current practice and changing from the conventional concept of aspirin maintenance to a ticagrelor-based regimen in the management of ACS.
Source: American Heart Journal - March 9, 2019 Category: Cardiology Source Type: research
Rationale and design for AMPLATZER Amulet Left Atrial Appendage Occluder IDE randomized controlled trial (Amulet IDE Trial)
Publication date: May 2019Source: American Heart Journal, Volume 211Author(s): Dhanunjaya Lakkireddy, Stephan Windecker, David Thaler, Lars Søndergaard, John Carroll, Michael R Gold, Hongfei Guo, Kyle J Brunner, James B Hermiller, Hans-Christoph Diener, Boris Schmidt, Lee MacDonald, Moussa Mansour, Brijeshwar Maini, Joseph LevineAimsThe Amulet IDE Trial is an ongoing, prospective, randomized, multi-national trial, designed to evaluate the safety and effectiveness of the AMPLATZER Amulet Left Atrial Appendage Occluder for stroke prevention in comparison to the WATCHMAN Left Atrial Appendage Closure Device in patients with ...
Source: American Heart Journal - March 4, 2019 Category: Cardiology Source Type: research
Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after PCI: An ancillary analysis from the RE-DUAL PCI trial
ConclusionDabigatran dual therapy reduced bleeding events irrespective of bleeding risk category and demonstrated similar efficacy regardless of stroke risk category when compared with warfarin triple therapy.
Source: American Heart Journal - March 4, 2019 Category: Cardiology Source Type: research
